AMAG Pharmaceuticals Inc (AMAG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH3552D
- Pages: 75
- October 2018
- Total Views:1188
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
AMAG Pharmaceuticals Inc (AMAG) develops and commercializes specialty pharmaceutical products with focus on maternal health, anemia management and cancer supportive care. It develops and markets products used to reduce the risk of preterm birth in women with a single baby who have a history of singleton spontaneous preterm birth; and products for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron and chronic kidney diseases. AMAG also provides services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units. The company offers its products through a direct sales force and a network of distributors. AMAG is headquartered in Waltham, Massachusetts, the US.
AMAG Pharmaceuticals Inc (AMAG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
AMAG Pharma Acquires Rights of Orphan Drug Candidate from Velo Bio 13
Private Equity 15
GI Partners Acquires CBR Systems from AMAG Pharma for USD530 Million 15
Licensing Agreements 17
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 17
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 19
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21
Equity Offering 22
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 22
AMAG Pharma Raises USD201 Million in Public Offering of Shares 24
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 250 Million 26
Debt Offering 27
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 27
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 29
Amag Pharma Completes Public Offering Of Notes Due 2019 For USD 200 Million 30
Asset Transactions 32
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 32
Acquisition 33
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 33
AMAG Pharma Acquires Lumara Health 35
AMAG Pharmaceuticals Inc-Key Competitors 37
AMAG Pharmaceuticals Inc-Key Employees 38
AMAG Pharmaceuticals Inc-Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Aug 02, 2018: AMAG Pharmaceuticals announces second quarter 2018 financial results and provides corporate update 40
May 03, 2018: AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance 42
Feb 27, 2018: AMAG Reports 2017 Financial Results and Company Update 44
Jan 08, 2018: AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance 46
Nov 02, 2017: AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights 48
Aug 03, 2017: AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 51
May 02, 2017: AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 55
Feb 14, 2017: AMAG Reports Fourth Quarter and Full Year 2016 Financial Results 57
Jan 09, 2017: AMAG Pharmaceuticals Provides Financial and Business Update 60
Corporate Communications 62
Aug 06, 2018: AMAG Pharmaceuticals Appoints Brian Robinson, M.D. as Senior Vice President of Medical Affairs 62
May 02, 2018: AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer 63
Sep 29, 2017: AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer 64
Sep 07, 2017: AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development 65
Apr 25, 2017: AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance 66
Mar 06, 2017: AMAG Announces Management Changes and New Commercial Appointments 67
Government and Public Interest 68
Dec 21, 2017: AMAG Pharmaceuticals Awards USD 300,000 in Grants to Further Research in Preterm Birth and Neonatal Health 68
Product News 69
02/02/2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration 69
Product Approvals 70
Jun 26, 2017: AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector 70
Apr 17, 2017: AMAG Submits Supplemental New Drug Application to FDA for Makena (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use 71
Other Significant Developments 73
Jun 11, 2018: AMAG Pharmaceuticals and March of Dimes Announce Collaboration to Improve Health of Mothers and Babies 73
Nov 08, 2017: AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children with Cerebral Palsy 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75
List Of Figure
List of Figures
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
List Of Table
List of Tables
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AMAG Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
AMAG Pharma Acquires Rights of Orphan Drug Candidate from Velo Bio 13
GI Partners Acquires CBR Systems from AMAG Pharma for USD530 Million 15
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 17
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 19
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 22
AMAG Pharma Raises USD201 Million in Public Offering of Shares 24
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 250 Million 26
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 27
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 29
Amag Pharma Completes Public Offering Of Notes Due 2019 For USD 200 Million 30
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 32
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 33
AMAG Pharma Acquires Lumara Health 35
AMAG Pharmaceuticals Inc, Key Competitors 37
AMAG Pharmaceuticals Inc, Key Employees 38
AMAG Pharmaceuticals Inc, Other Locations 39
AMAG Pharmaceuticals Inc, Subsidiaries 39
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
AMAG Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
AMAG Pharmaceuticals Inc (AMAG) develops and commercializes specialty pharmaceutical products with focus on maternal health, anemia management and cancer supportive care. It develops and markets products used to reduce the risk of preterm birth in women with a single baby who have a history of singleton spontaneous preterm birth; and products for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron and chronic kidney diseases. AMAG also provides services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units. The company offers its products through a direct sales force and a network of distributors. AMAG is headquartered in Waltham, Massachusetts, the US.
AMAG Pharmaceuticals Inc (AMAG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
AMAG Pharma Acquires Rights of Orphan Drug Candidate from Velo Bio 13
Private Equity 15
GI Partners Acquires CBR Systems from AMAG Pharma for USD530 Million 15
Licensing Agreements 17
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 17
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 19
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21
Equity Offering 22
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 22
AMAG Pharma Raises USD201 Million in Public Offering of Shares 24
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 250 Million 26
Debt Offering 27
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 27
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 29
Amag Pharma Completes Public Offering Of Notes Due 2019 For USD 200 Million 30
Asset Transactions 32
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 32
Acquisition 33
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 33
AMAG Pharma Acquires Lumara Health 35
AMAG Pharmaceuticals Inc-Key Competitors 37
AMAG Pharmaceuticals Inc-Key Employees 38
AMAG Pharmaceuticals Inc-Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Aug 02, 2018: AMAG Pharmaceuticals announces second quarter 2018 financial results and provides corporate update 40
May 03, 2018: AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance 42
Feb 27, 2018: AMAG Reports 2017 Financial Results and Company Update 44
Jan 08, 2018: AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance 46
Nov 02, 2017: AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights 48
Aug 03, 2017: AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 51
May 02, 2017: AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 55
Feb 14, 2017: AMAG Reports Fourth Quarter and Full Year 2016 Financial Results 57
Jan 09, 2017: AMAG Pharmaceuticals Provides Financial and Business Update 60
Corporate Communications 62
Aug 06, 2018: AMAG Pharmaceuticals Appoints Brian Robinson, M.D. as Senior Vice President of Medical Affairs 62
May 02, 2018: AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer 63
Sep 29, 2017: AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer 64
Sep 07, 2017: AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development 65
Apr 25, 2017: AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance 66
Mar 06, 2017: AMAG Announces Management Changes and New Commercial Appointments 67
Government and Public Interest 68
Dec 21, 2017: AMAG Pharmaceuticals Awards USD 300,000 in Grants to Further Research in Preterm Birth and Neonatal Health 68
Product News 69
02/02/2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration 69
Product Approvals 70
Jun 26, 2017: AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector 70
Apr 17, 2017: AMAG Submits Supplemental New Drug Application to FDA for Makena (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use 71
Other Significant Developments 73
Jun 11, 2018: AMAG Pharmaceuticals and March of Dimes Announce Collaboration to Improve Health of Mothers and Babies 73
Nov 08, 2017: AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children with Cerebral Palsy 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75
List Of Figure
List of Figures
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
List Of Table
List of Tables
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AMAG Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
AMAG Pharma Acquires Rights of Orphan Drug Candidate from Velo Bio 13
GI Partners Acquires CBR Systems from AMAG Pharma for USD530 Million 15
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 17
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 19
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 22
AMAG Pharma Raises USD201 Million in Public Offering of Shares 24
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 250 Million 26
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 27
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 29
Amag Pharma Completes Public Offering Of Notes Due 2019 For USD 200 Million 30
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 32
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 33
AMAG Pharma Acquires Lumara Health 35
AMAG Pharmaceuticals Inc, Key Competitors 37
AMAG Pharmaceuticals Inc, Key Employees 38
AMAG Pharmaceuticals Inc, Other Locations 39
AMAG Pharmaceuticals Inc, Subsidiaries 39
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
AMAG Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020